• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

New sedative for dogs is launched

July 6, 2022
dvm360 Staff
dvm360, dvm360 August 2022, Volume 53, Issue 8
Pages: 18

Dechra’s alpha-2 combination drug is indicated to minimize stress surrounding canine sedation

A new veterinary drug for sedation and pain relief in dogs is now available. The drug, an alpha-2 agonist medetomidine and vatinoxan combination (Zenalpha; Vetcare Oy and Dechra), is indicated for use as a sedative and analgesic in dogs to facilitate clinical examinations, clinical procedures, and minor surgical procedures, according to an announcement by Dechra.1

The combination sedative was developed by Vetcare Oy in Finland and Dechra holds the marketing authorization in the United States. The drug received FDA approval in April 2022, and was the first approval marked by the FDA for vatinoxan.2

The combination of the alpha-2 agonist medetomidine and vatinoxan provides a unique balance of central and peripheral activity that minimizes cardiovascular adverse effects while maintaining the sedative and analgesic properties of medetomidine.1

“Veterinarians routinely utilize sedatives in their daily practice to ensure the safety and comfort of their patients and the hospital team. Current canine sedatives carry some concern for cardiac function while the patient is sedated,” said Nancy Zimmerman, DVM, group business development director at Dechra, in an organizational press release.1

“[The] combination of medetomidine and vatinoxan addresses one of those key concerns about patient safety during sedation by minimizing cardiovascular [adverse] effects,” she added.1

Advertisement

According to Dechra, the alpha-2 agonist combination has a short duration of sedation—approximately 45 minutes in most dogs, with a mean duration of 38 minutes.1

“The veterinary hospital team can spend less time waiting for the patient to become sedated and recover, and more importantly to the pet owner, the dog can return home sooner,” Zimmerman stated in the release.1

Because of the quick recovery time and less cardiovascular depression, the use of reversal agents may not be needed, which Dechra officials indicated that it hoped can save time and decrease costs for clinics.1

The new combination sedative is available in 10 mL multi-dose glass vials, through Dechra-approved distributors, according to the company.1

References

  1. Dechra introduces Zenalpha (medetomidine and vatinoxan hydrochlorides injection) as canine sedative that helps minimize cardiovascular side effects. News release. Dechra Veterinary Products. July 6, 2022.
  2. FDA approves new combination injection for sedation and pain relief in dogs. Dvm360®. April 5, 2022. Accessed July 6, 2022. https://www.dvm360.com/view/fda-approves-new-combination-injection-for-sedation-and-pain-relief-in-dogs
download issueDownload Issue: dvm360 August 2022

Related Content:

MedicalFDAdvm360 August 2022
FDA and European Union expand Mutual Recognition Agreement to include animal drugs
FDA and European Union expand Mutual Recognition Agreement to include animal drugs
Drug for acute onset of canine pancreatitis is launched on the US market
Drug for acute onset of canine pancreatitis is launched on the US market
Diagnostics for a thoracic trauma patient
Diagnostics for a thoracic trauma patient

Advertisement

Latest News

Humanimal Trust joins World Federation for Animals

News wrap-up: This week’s headlines, plus Kansas State University College of Veterinary Medicine presents Temple Grandin, PhD, MS, with an honorary degree

Can our Pride panel answer these LGBTQ+ trivia questions?

Creating inclusive spaces for the LGBTQ+ community in vet med

View More Latest News
Advertisement